Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of SNK01 in Plaque Psoriasis
NCT03894579Phase 1Completed
- Sponsor
- NKGen Biotech
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of troculeucel in plaque psoriasis, sponsored by NKGen Biotech. Primary endpoint: Dose-Limiting Toxicity at 8 weeks. Started Jul 2019; status: completed.
02
Drugs
troculeucel
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03894579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894579.